Article
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2016
Tan Daniel S W, Yom Sue S, Tsao Ming S, Pass Harvey I, Kelly Karen, Peled Nir, Yung Rex C, Wistuba Ignacio I, Yatabe Yasushi, Unger Michael, Mack Philip C, Wynes Murry W, Mitsudomi Tetsuya, Weder Walter, Yankelevitz David, Herbst Roy S, Gandara David R, Carbone David P, Bunn Paul A, Mok Tony S K, Hirsch Fred R
Abstract excerpt
Mutations in the epidermal growth factor receptor gene (EGFR) represent one of the most frequent "actionable" alterations in non-small cell lung cancer (NSCLC). Typified by high response rates to targeted therapies, EGFR tyrosine kinase inhibitors (TKIs) are now established first-line treatment options and have transformed the treatment paradigm for NSCLC. With the recent breakthrough designation and approval of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.